NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis $3.95 +0.02 (+0.51%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.91 -0.04 (-1.01%) As of 08/7/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock About Titan Pharmaceuticals Stock (NASDAQ:TTNP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Titan Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.95▼$4.0050-Day Range$3.86▼$5.1352-Week Range$3.03▼$14.80Volume1,434 shsAverage Volume45,604 shsMarket Capitalization$3.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. Read More Titan Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreTTNP MarketRank™: Titan Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Titan Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Titan Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Titan Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTitan Pharmaceuticals has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Titan Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.91% of the float of Titan Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTitan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Titan Pharmaceuticals has recently decreased by 99.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTitan Pharmaceuticals does not currently pay a dividend.Dividend GrowthTitan Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.91% of the float of Titan Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTitan Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Titan Pharmaceuticals has recently decreased by 99.71%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Titan Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Titan Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.72% of the stock of Titan Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 31.49% of the stock of Titan Pharmaceuticals is held by institutions.Read more about Titan Pharmaceuticals' insider trading history. Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTNP Stock News HeadlinesTITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5 at 9:24 PM | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comCritical AI announcement set to ignite AI 2.0 While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly taking advantage of a reliable volatility pattern. A veteran trader just revealed how his strategy cuts through the noise—using fast trades, clear rules, and no overnight risk. | Timothy Sykes (Ad)Titan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | finance.yahoo.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27, 2025 | globenewswire.comSee More Headlines TTNP Stock Analysis - Frequently Asked Questions How have TTNP shares performed this year? Titan Pharmaceuticals' stock was trading at $3.26 at the beginning of the year. Since then, TTNP shares have increased by 21.2% and is now trading at $3.95. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Wednesday, May, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings5/14/2025Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TTNP CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-145.92% Return on Assets-129.20% Debt Debt-to-Equity RatioN/A Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$180 thousand Price / Sales19.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book1.48Miscellaneous Outstanding Shares910,000Free Float907,000Market Cap$3.59 million OptionableOptionable Beta1.29 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TTNP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.